Most write-ups treat Selank as an anxiety peptide with an odd Russian backstory. That framing skips the first half of the molecule's biography. Selank is a synthetic analogue of tuftsin — a four-amino-acid fragment (Thr-Lys-Pro-Arg) cleaved out of the heavy chain of human immunoglobulin G, which is about as immunological a pedigree as a peptide can have. A large slice of the published Selank literature is immunology and virology, not psychiatry. If you're researching what is Selank and what the evidence actually supports, the immune data is the half that rarely makes the summary.

This post walks through that immune literature, where it's strong, where it's animal-only, and what it means for readers in Australia — where Selank remains an unapproved therapeutic good. For the compound profile and dosing-research background, see our Selank page.

The tuftsin lineage: why Selank was built at all

Tuftsin is an endogenous immunostimulating tetrapeptide released from IgG. It's potent but fragile — chewed up quickly by peptidases. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences extended it at the C-terminus with Pro-Gly-Pro, producing the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro: Selank. The added glyproline tail was a stability fix, not a psychiatric design choice.

So the anxiolytic profile — GABA-A modulation, effects on enkephalin-degrading enzymes, BDNF changes — emerged from a molecule whose parent compound's day job was immune signalling. Both sets of effects plausibly come from the same structure, and the peptide has been described in the Russian literature as an immunomodulator at least as often as a nootropic.

What the immune research actually shows

Inflammation gene expression: broad, fast, and preclinical

The most concrete immune data is transcriptomic. In a mouse spleen study, a single intraperitoneal dose of Selank (100 µg/kg) shifted expression across a panel of 84 inflammation-related genes — chemokines, cytokines and their receptors — with significant changes in 34 of them at 6 and 24 hours. Follow-up work tracked the time course of specific targets (C3, Casp1, Il2rg, Xcr1) and compared Selank with its short fragments.

This is real, replicated-within-a-lab-group data. It is also entirely rodent, measured in gene expression rather than clinical outcomes, and tells you that Selank touches inflammatory signalling — not that it improves any disease state.

Cytokines under stress: animal model

A rat "social stress" model reported that stress elevated IL-1β, IL-6, TNF-α and TGF-β1, and that Selank brought those values back toward control levels. Directionally interesting; again, animal-only, and from the same Russian research network that developed the compound. Independent replication outside that network is thin.

The one human immune dataset

There is a small human signal, and it is worth being precise about it. A 2008 study in Zhurnal Nevrologii i Psikhiatrii (Uchakina and colleagues) measured cytokine gene expression in patients with anxiety-asthenic disorders treated with Selank. The reported finding was suppression of elevated IL-6 gene expression in patients, with no significant effect on IL-6 expression in healthy individuals.

Caveats matter here. This is one small study, published in Russian, in a patient group selected for psychiatric rather than immune indications, with no placebo-controlled immune endpoint of the kind a regulator would want. It belongs to the same cluster of three small Russian human trials — the newest from 2015 — that constitutes the entire human evidence base for Selank. It has not been replicated by an independent group.

Antiviral activity: the most over-quoted part

Selank has been tested against influenza A (H3N2) in cell culture and in mice, with antiviral effects reported in both, and the proposed mechanism involving induction of interferon-alpha gene expression and modulation of Th1/Th2/Treg balance. Separate work on Selank's structural fragments found the tetrapeptide Arg-Pro-Gly-Pro showed activity against influenza A and B, H5N1, HSV-1 and HSV-2, CMV and encephalomyocarditis virus in experimental systems.

Read that carefully: these are in vitro and animal infection models, the strongest effects came from pre-exposure dosing schedules, and part of the activity attributed to "Selank" actually sits with a fragment. There is no human antiviral trial of Selank. Any marketing that presents Selank as an antiviral or "immune booster" for people is running well ahead of the data.

Selank Australia: the legal and regulatory position

On the Australian regulatory question — is Selank legal in Australia — the answer is the same nuanced one that applies across much of this space. Selank is unscheduled in the Poisons Standard, meaning it isn't a controlled substance. But it is not on the Australian Register of Therapeutic Goods, which makes it an unapproved therapeutic good. It cannot be lawfully supplied or advertised in Australia for therapeutic use outside specific pathways such as the Special Access Scheme, Authorised Prescriber arrangements, or personal importation, each with its own conditions.

That distinction bites hardest with the immune and antiviral material above. Making antiviral or immune-modulating claims for an unapproved good in Australia sits squarely inside the TGA's advertising restrictions — and on evidence this preliminary, it wouldn't survive a substantiation check anyway.

Two more anchors worth having:

  • Anti-doping: Selank is not on the WADA 2026 Prohibited List. Athletes should still confirm current status directly with their sport's authority, since lists are revised annually and non-listed status is not an endorsement.
  • Overseas signals: in Russia, Selank is registered for mild anxiety — a national approval, not an FDA, EMA or TGA one. In the United States, Selank acetate was removed from Category 2 of the FDA's interim 503A bulk drug substances list in 2024 after the nominator withdrew the nomination — a procedural withdrawal rather than a safety finding, but also a sign that nobody is currently pushing it through a formal compounding pathway.

What this changes for how you read Selank claims

Three practical filters:

  1. Check which half is being quoted. If a page cites impressive immune or antiviral numbers, ask whether the study was in mice, in a dish, or in people. For Selank's immune work, the honest answer is nearly always the first two.
  2. Check whether it was Selank or a fragment. The antiviral fragment data is a genuinely interesting research thread and a genuinely misleading marketing tool.
  3. Check the network. Most Selank research traces back to one Russian institutional lineage. That's not disqualifying, but independent replication is the thing the field is missing, and it's the reason no Western regulator has evaluated it.

Browse the wider peptides library for how other compounds in this class compare, and join the free updates list if you'd like new evidence reviews as they're published.

FAQ

What is Selank?

Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia as a stabilised analogue of tuftsin, an immune-signalling fragment of immunoglobulin G. It's studied for anxiolytic effects and, less publicly, for immune and antiviral activity.

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard but is not registered on the ARTG, making it an unapproved therapeutic good. It can't be lawfully supplied or advertised for therapeutic use in Australia outside pathways like the Special Access Scheme, Authorised Prescriber arrangements or personal importation.

Does Selank boost the immune system?

There's preclinical evidence that Selank shifts inflammation-related gene expression and cytokine levels in rodents, plus one small 2008 Russian human study reporting reduced IL-6 gene expression in patients. That is not enough to support an immune-boosting claim in people, and no controlled human immune trial exists.

Is Selank banned by WADA?

No — Selank is not listed on the WADA 2026 Prohibited List. Athletes should still verify current status with their national anti-doping body, as lists are updated each year and unlisted does not mean risk-free.

Sources

This article is information only, not medical advice. Selank is not approved by the TGA and is an unapproved therapeutic good in Australia; retatrutide.net.au is independent and does not sell or supply any compound.